ADMA Biologics (NASDAQ:ADMA) Downgraded by Zacks Research to “Strong Sell”

ADMA Biologics (NASDAQ:ADMA) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Several other equities research analysts also recently issued reports on ADMA. Canaccord Genuity Group lowered their price objective on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Cantor Fitzgerald restated a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Finally, Mizuho lowered their price objective on shares of ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $19.00.

ADMA Biologics Trading Down 2.8%

Shares of ADMA Biologics stock opened at $7.92 on Tuesday. The company’s fifty day simple moving average is $10.04 and its 200-day simple moving average is $14.80. The company has a market cap of $1.84 billion, a price-to-earnings ratio of 11.65 and a beta of 0.83. The company has a current ratio of 6.95, a quick ratio of 3.93 and a debt-to-equity ratio of 0.51. ADMA Biologics has a 1 year low of $7.21 and a 1 year high of $22.37.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.19. The business had revenue of $114.49 million for the quarter, compared to the consensus estimate of $139.98 million. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. ADMA Biologics’s quarterly revenue was down .3% on a year-over-year basis. During the same quarter last year, the company posted $0.11 earnings per share. As a group, sell-side analysts expect that ADMA Biologics will post 0.84 EPS for the current year.

Insiders Place Their Bets

In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction on Monday, March 9th. The shares were sold at an average price of $15.63, for a total transaction of $157,800.48. Following the sale, the chief operating officer owned 466,600 shares in the company, valued at $7,292,958. The trade was a 2.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jerrold B. Grossman purchased 12,500 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were acquired at an average price of $8.01 per share, for a total transaction of $100,125.00. Following the purchase, the director directly owned 513,884 shares of the company’s stock, valued at approximately $4,116,210.84. This represents a 2.49% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On ADMA Biologics

Institutional investors have recently bought and sold shares of the business. Westfield Capital Management Co. LP bought a new position in shares of ADMA Biologics during the third quarter valued at $74,866,000. Janus Henderson Group PLC lifted its holdings in shares of ADMA Biologics by 3,906.1% during the fourth quarter. Janus Henderson Group PLC now owns 3,936,419 shares of the biotechnology company’s stock valued at $71,820,000 after acquiring an additional 3,838,158 shares during the period. Capital Research Global Investors lifted its holdings in shares of ADMA Biologics by 104.0% during the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock valued at $121,067,000 after acquiring an additional 3,383,559 shares during the period. Caligan Partners LP bought a new position in shares of ADMA Biologics during the third quarter valued at $38,653,000. Finally, UBS Group AG lifted its holdings in shares of ADMA Biologics by 129.9% during the fourth quarter. UBS Group AG now owns 4,569,343 shares of the biotechnology company’s stock valued at $83,345,000 after acquiring an additional 2,581,670 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.